C - Chemistry – Metallurgy – 12 – Q
Patent
C - Chemistry, Metallurgy
12
Q
C12Q 1/70 (2006.01) A61K 45/00 (2006.01) C12Q 1/02 (2006.01) G01N 33/50 (2006.01) G01N 33/566 (2006.01) G01N 33/569 (2006.01) G01N 33/68 (2006.01) G01N 33/74 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2471744
The present invention permits data, derived from bGH-Tg mice in the context of crosstalk between cytokine and chemokine responses, to aid in understanding the functional role of this chemokine/chemokine receptor pair. As the only models available to date were thoses in which the CXCR4 or CXCL12 deletion is lethal before birth the present invention provides means for relating cytokine- mediated effects to the functional role of CXCR4 inactivation in postanatal life. A method is provided for treating a human having a disease associated with CXCR4-dependent HIV comprising administering to said human a therapeutically anti-viral effective amount of a molecule that induces the expression of SOCS3 and a pharmaceutically acceptable carrier. A method is provided for treating a human having a disease associated with CXCR4-dependent HIV, wherein said molecule binds to GHR.
La présente invention permet d'obtenir des données dérivées de souris bGH-Tg, concernant l'interaction entre des réponses de cytokine et de chimiokine, servant à comprendre le rôle fonctionnel de la paire de récepteurs chimiokine/chimiokine. Les seuls modèles disponibles jusque là font intervenir une délétion de CXCR4 ou de CXCL12 qui s'avère être létale avant la naissance. Selon l'invention, il est possible d'associer les effets à médiation par cytokine au rôle fonctionnel de l'inactivation de CXCR4 dans la vie postnatale. L'invention concerne un procédé de traitement d'un humain soufrant d'une maladie associée au VIH dépendant de CXCR4, consistant à administrer à cet humain une quantité thérapeutique à effet antiviral d'une molécule provoquant l'expression de SOCS3, et un porteur pharmaceutiquement acceptable. Dans un autre mode de réalisation, ladite molécule se lie à GHR.
Martinez-Alonzo Carlos
Mellado Mario
Rodriquez-Frade Jose
Consejo Superior de Investigaciones Cientificas
Moffat & Co.
Pharmacia Spain S.a.
LandOfFree
Functional inactivation of cxcr4-mediated responses in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Functional inactivation of cxcr4-mediated responses in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Functional inactivation of cxcr4-mediated responses in... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2007682